| |
According to the FDA database in early 2002, since its launch in early 1998 sibutramine (Meridia) has been associated with 29 deaths including 19 from cardiovascular adverse effects in people using this minimally effective drug.
In mid-March of 2002, sibutramine’s use was suspended in Italy because of two cardiovascular deaths, and its safety was reviewed in other European countries where, in the United Kingdom (UK) and France, there had been a total of 103 serious adverse reaction reports in people using the drug, including two deaths in the U.K.
|
|
